Brad Moore on Leveraging Blockchain to Improve Outcomes for Medical Cannabis Patients | #HashtagFinance

CSE's Barrington Miller chats with Brad Moore, CEO of Global Cannabis Applications Corp. (CSE:APP) about his company's ambitions as a technology company that strives to improve medical cannabis patients' outcomes through the gathering and analysis of deep data.

Here's an overview of what Barrington and Brad cover in this edition of the #HashtagFinance podcast:

1.10 - Virtual work is nothing new for Brad and his international team.
3:35 - GCAC's Israeli technology connection.
6:01 - How Brad has applied his military mindset into the cannabis/tech industries.
9:53 - The impact of the early 2018 cannabis "craze" on the company.
13:54 - Defining 2020 as the year of the (delayed) balance sheet.
15:46 - The application of blockchain on their business model.
18:20 - Building data points during COVID.
19:35 - The differentiator.
23:53 - The power of data to improve patient incomes.
28:47 - What a potential exit path looks like for the company. 

Current approval processes for medical treatments generally start with a formulation of elements. The objective of any clinical study is to ensure efficacy, and safety, within a fixed sampling size. However as cannabis is a plant, and each plant is unique, the challenges have been in ensuring that each gram tested would provide a consistent result. In response to these challenges, GCAC has developed a patent-pending data model called, Seed to Seed.

GCAC's approach is to measure an individual’s unique treatment experience on a per dosage basis. By digitally measuring both the biometric & anecdotal feedback and comparing that to others using the same or similar products on a large scale, GCAC can provide an averaged efficacy rating for the treatment used. This is accomplished through a proprietary system of mobile applications, heart monitoring biometrics, Artificial Intelligence and machine learning. When integrated with blockchain seed to sale solutions, GCAC technology will be able to recommend “how to treat ailment X with product Y at a given point in time under a set of circumstances”. By securing this information on an EU GDPR complaint blockchain, their data outputs are comparable to results generated by a regulatory approval process.

Related links
http://cannappscorp.com/
https://thecse.com/en/listings/technology/global-cannabis-applications-corp

🔴 Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe

#alwaysinvested

STAY CONNECTED WITH THE CSE
=============================

📧 - NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe
🎧 - PODCAST: https://blog.thecse.com/cse-podcasts/
📸 - INSTAGRAM: https://www.instagram.com/canadianexchange/
🤝 - LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
👥 - FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
🐦 - X: https://x.com/CSE_News
📝 - BLOG: https://blog.thecse.com/
🖥 - WEBSITE: https://thecse.com/
📖 - MAGAZINE: https://issuu.com/thecse/docs

©2024 CNSX Markets Inc. All rights reserved.

Transcript

Speaker 1: 0:00

Hey, it's James here welcoming you to this presentation of the hashtag finance podcast. This is just a reminder that if you like video, all of our CEO and expert interviews are featured on the hashtag finance playlist on CCTV, including the show that you were about to listen to remember that a CSC space TV on YouTube. And finally, this is just a friendly reminder that the views information or opinions expressed during the podcast are solely those of the individuals involved and do not necessarily represent those of the Canadian securities exchange and its employees. So happy listening, and now enjoy the show. This is hashtag finance presented to you by the Canadian securities exchange the exchange for entrepreneurs with your host Barrington Miller.

Speaker 2: 0:52

All right, welcome to an edition of hashtag finance. I'm your host Barry Miller director of listed company services, not the Canadian securities exchange today. I'm here with mr. Brad Moore, CEO of global cannabis application Corp. How are you doing today? I'm getting married. 10. How are you? I'm good. We are broadcasting from the second floor of my house visually. It's the 72nd floor at first Canadian place. We haven't been doing that for a while. We are taking it live on, on zoom. So tell us how you're doing. How's the family. How is covert treating you? They're good. Um, yeah, you know, it it's been crazy and you know, for me and my team personally, uh, we all work remotely cause I got a bunch of people in Asia. I got people in Lithuania. I got somebody in Spain. I got somebody in Montreal, the CFO and some of my market people are in Vancouver. So we're used to working out of the house, especially I've got this weird work day, right. That starts at like 8:00 PM and goes to 1:00 AM and then I get up for the markets and then that goes till two. And then so my everybody else afternoon is my evening. Right. And so I've got it. So for a lot of us, it's not, it hasn't really been that much different. You know what I mean? Cause we all we've been zooming before zooming was cool. Let's just put it that way. Right. And so of course we were invested in zoom and Walker shares and yeah, well, yeah, right. That's it. That's why I don't have to raise money for the County. I just keep rolling that in my Tesla stock. Of course. Right. Of course once I was out of a while ago, unfortunately, um, you know, for the family, it's been weird. Uh, the kids live in Montreal and, and so I didn't usually I see them every week and a half or sorry, every, uh, um, uh, like a maps MoMA of like four weeks gap. Right, right. Um, so all of a sudden, I didn't see him for four and a half, five months and, and tragically, the grandfather actually passed from COVID. It was a hard year. Yeah. It was just, it was, it was just, you know, it's surreal. Cause we all feel the impact of it and our work lives in this and we've watched the news and then, you know, somebody who gets it and it just, it, it, it really does bring it home, but, uh, they're, they're, they're much better. My son, we were able to kinda, you know, do a, do a search and rescue to get them on a bunch I'll get into to the more temperate West coast where it's like, he's not melting like a stick of butter and on a daily basis. And so we're, uh, we're trying to enjoy the time together, go through all this. So I thank you for us.

Speaker 3: 3:31

No, no problem. Um, so your company, tell us, tell us a little bit about, uh, what your company is doing.

Speaker 2: 3:42

Sure. Well, it's, it's, it's, uh, you know, you and I have talked and I've talked about this. A lot of people it's, it's a big story, right? It's, it's, it's a very big project and I think it's a big project because if we could have, if cannabis could have could, if it was what it could be, we wouldn't, there wouldn't be a need for us. We're and we're really about advocacy, right? We're this is we, we look, the first step is getting it out of the ground and the last step is getting somebody to use it, um, in an efficient, safe manner. Um, and you know, we, we, we know where it's hidden stumbling blocks just from not even about evaluation, but from growing an importation, exportation importation, and getting doctors and patients comfortable with it. You know, our focus is not the 1% of the 1% who were using it. We were getting it out advice from their bud tender and spoke, growing into 2% and 1%, 3%, 4% of 1%. And that means we need data. And so we're essentially a data company. We're a medical cannabis data company in that spectrum CBD is in there too, because it's a function of, of, of the, let's say the cannabis family per se. Right. Um, but that's what we are, is we're a data company. Um, and we're an efficacy instead of just being like aggregating clinical study information, we're an efficacy data company and we're driven by, we do that through smart technologies, um, biometrics, blockchain, AI, all the cool buzzwords, right? Yeah. And, and, and it's a conversation I've had a lot, but we've built a world class system using some really smart guys and primarily out of Israel, um, who had been leaders in medical cannabis research and development of it as an actual, I guess, an old product. Right. So that's what we do.

Speaker 3: 5:39

Let's uh, let's take one step back. Tell us about you.

Speaker 2: 5:44

Oh, me.

Speaker 3: 5:46

You know, just, just a reminder, this isn't family, this is a family show. So I'm like, how did you, how did you get here? And even further back, how fundamental become a global Canada?

Speaker 2: 6:01

Yeah. So, um, I got, actually, I got hired into it. I was a chief revenue officer at a FinTech company in Vancouver. Um, you know, when I moved back to Vancouver for Montreal in 2014, I was at a FinTech company. And then, you know, I'm, I'm much more entrepreneurial by nature. You know, I like a challenge. I'm an ex army guy. So if there's a challenge, if the walls, hi, I'm all perfect. If I get over it, I'm all like, how do you make it higher? Right. And if I can't do that, I'll get a charge and blow up the wall and go through it. Like, it's just, everything is just an opportunity. It's not necessarily an obstacle. And I, uh, when I took over a fundamental, I was recommended and I met some of the people on the board and they said, we think you could help us. Or we're kind of doing this whole student buy sell thing. And I said, well, that's interesting. I said, what's really interesting is you have a publicly traded vehicle. Um, and you know, you're in the app game, which is good. I said, my sense is that Facebook is going to do something which they did with their marketplace. Um, and at the time I was in investor, I had only shares him cannabis. And I would like, a lot of people was enjoying the upside to, you know, if he owned a license on a piece of land or a$10 million company. Right. So start, yeah, just start. Right. And so, um, when I looked at it, you know, my thing was, was I go, well, look, and I, and I remember looking at a clinical study one day and I go, this, this won't work for Canada. So it won't work. You can't do an approval process. And it's very simple. You know, I've talked about this, a lot of people, you and I talked about this, it's a plan. So when you test in a grant, there's no guarantee it's going to be the next brand that somebody in that study group test, it's going to be the same, even if it's cloned or it's genetically reproduced, it's an individual living unique organism, and then you have a human body. So how do you get average based efficacy? That was the thing. And so that started a journey and it started a lot of conversations and I realized that we could do it, but we're going to have to come at it from the other side, we're going to, it was going to be not, it was going to be about big data. Right. And so it started conversations with, believe it or not with people in Lithuania about blockchain. Then I went to Australia and then I ended up, um, talking to his Railey's, which I knew for many moons ago when I used to work at Kodak. Um, and so I, I, you know what, honestly, if I looked at the Israeli model and I said, how do I commercialize this? How do I make it bigger? Right. And how do I make the sampling size? Just bigger. How do I get there? And what does that look like? And that's really what started it. And that actually, honestly, so that was kind of like, we changed names around, you know, may ish, 2017 with just a really honest with just, I hate to say this, but just like a glimpse, a vision. And we're all like, cause we're not gonna do anything if we don't make this well, apparently if you're growing it, that's all you need is a glimpse of a vision. So I figured why can't I, but yeah, so we, we did it. And then we did a lot of research. We spent a lot of time, you know, a lot of time, a lot of talking to really smart PhDs and doctors and scientists and actually clinical practitioners, people that doctors that were treating patients. And that's very important because when you look at somebody's experience, you have to look the totality of their experience with any medicine. And if you can't determine that in a clinical study, you have to look at a per user basis. Right. And so that started it 2019, we came up with the, you know, the development plan. We came up with the end game and 2019 or 2017, sort of the end of it. We started to fundraise

Speaker 3: 9:53

Let's let's delve into that. Let's talk into that timeframe. End of your 2017 to 2019. Um, I think it's safe to say, and the opinions expressed on this show are truly my own, right? Those don't necessarily reflect those of the CSC. Uh, evaluations were kind of nutty. Uh, they were in some cases absurd, um, no basis. And we saw a massive run-up and there are companies that maybe deserved it. Uh, I think a lot of companies didn't, a lot of companies got swept up in the, in the updraft. Um, but like any coin, there's two sides and, you know, companies, companies tumbled

Speaker 2: 10:44

Yeah. 100%. And when you're a small cap, you know, it's kind of like a minnow, the tide goes in, the tide goes out, you're not strong enough to swim out of that. You can just float along. And hopefully as your business develops, you get a little pair of fence. You can mitigate some of that. But no, we definitely, we definitely got caught up in that at the beginning. And, uh, because we had some buzzwords really, um, and you know, our development cycle kind of started, but I remember that fateful morning, January 3rd, and some, you know, my flight, I was like lying on the bed. And I looked over and like, focus, I flashing like a Christmas DRAM, pretty sure Christmas is over. And it was like, are you watching this? And I was like, what? And it's like, you know, and it was a, it was, it was like, you know what, we haven't said anything. And this is my first gig as a Pubco CEO. So I'm very grounded in reality. And I think it was an ex army guy and he's been many different places. I'm all like, okay. I was like, Oh, okay. That's interesting. You know, and I'm all like, but you know, every time you pick up a Hill, you get to enjoy or uninjured the other, you know, the downside. Right. Um, and so, yeah, I agree

Speaker 4: 11:54

With you. I think my sense is, and it's just my opinion, you know, um, that, you know, it would've been made very clear by the existing, um, uh, government regime that they were going to go back. They were going to go recreational. So he were trying to, you know, you're serving cannabis in the Canadian grain market. Right. It's not even legal per se. And so everybody's piling in and then that language comes out that we're going to go recreational. So now it's not even about the SNL, you know? Right. It's kinda like, it's like, okay, rum is really good for, you know, cough for a coal. Right. And now we're just going to sell them the liquor store and everybody can have it prohibitions over. And so I wonder how much of that market stuff, which is predicated on the fact that we need, they thought the market was just, you know, it was gonna blow open. Right. And then when it didn't shake out, like don't go downtown. Um, and, but I a true medical company. Right, right. It's never real. I hate to say it. It's never really been that much about the Canadian market. Right. It's been about Europe. It's about, about place of heavy, heavily regulation regulated, where there was not a lot of, not a lot of movement forward because of the regulation. And that's what we want.

Speaker 3: 13:07

Well, we were always talking, um, we did, we did a special five 20, so that was a may instead of four 20. And we featured a bunch of cannabis companies check it out on CSC, underscore TV on YouTube. Um, and 2020 is a year of the balance sheet, 2020 is, um, what do you really have? What are you really doing? And I think we've seen some of the, some of the companies definitely emerged, uh, some of the multistate operators again in the U S but there were a lot of companies that are now sort of struggling, trying to find their way because they may not have had as strong a business plan, um, as before

Speaker 4: 13:54

A hundred percent. Right. And, you know, it's, like I said, it's look this at, I think 2020 is the year of the delayed balance sheet because COVID right. So it's all, we've all kind of had to adjust. I knew that, uh, look, we, we were coming out of the gate, nice, strong in the alignment. And it was literally March where like, okay, we're gonna come out and we'll have this in place. And then, you know, it's the building block started getting chunked away. So, you know, for us as a company, you said, look, we're small cap. We've got to work with what we've got to look nobody's given up. And nobody died from any crap in it for the last six months. So that's fine. So we just knuckled down and we worked on those strategic partnerships. You know, one of the things, um, when I look at our business development, 2008 and I, how much stuff we built, all the big news. And then we came out and we, we determined in 2019 and saints were kind of probably to part a little bit, I think, in the overall market and getting swept up in that is that we knew we saw a couple of key things and it was that the EU said, we need to decriminalize this. We need to take it off. Schedule one, go. And then there was,

Speaker 3: 15:03

Bye

Speaker 4: 15:04

This information, this information, this information, this information, this is where you saw the explosion of the seat, the sale. Right, right. You know, the regulatory guys that could get you through the process and get your product in country. And then every country had its own little rules and kind of stuff going on. They knew there were some of the United States. And then, then there, then there came. The thing is, but that didn't increase the 1% of the 1%. Cause like, as a doctor, you're going put your name, reputation, a potential lawsuit on the line did write something. When you don't know what's going to happen, you're going to take a company's product sheet and hope.

Speaker 3: 15:36

That's a, that's a really good point. Um, and not a lot of people have discussed that because doctors don't have to put their name on it. And it's literally every time they prescribe it's.

Speaker 4: 15:46

So if you look as if people go back and they look at the patent that I filed cannabis on the blockchain, which describes the seed, the seed cross soil, no seed the sale. But what if I took out the unique identifier and I grabbed that and ingest it into my smart aide blockchain, and then I put that onto somebody handheld onto our consumer based device, right? And then they were wearing a biome, like an Apple watch that was biometrically st with this. So every time they ingested something, all the data from their heart rate, all the way their user experience got recorded against ag land. And then I fed that back against 300 or$500 people doing the exact same treatment. And I came up with an average efficacy. And then I measure that over time and kept updating the system like, wow, like if you're a doctor, that's the closest thing you're going to get to a full on scale. So our objective over the next two years is we're going to have 465,000 people right. Doing that with us. And it's not a big number. Like if you look at like companies like Leafly and all these other ones that have millions and millions of people want to know, and you know, we have a very strong acquisition, uh, program to go out and focus on the consumer. That's I think when I talk to investors go, what's different between your launch in 2019 and what you're doing now, I go, well, look, retailers respond to the market demand, right? So we're going to create the market demand. We're going to go out, we're going to create our technologies. Biggest thing that we've done recently is working, using a biometric component. Cause you know, I, people do too much to see. They might kind of lie about some of the answers. So we're going to measure their heart rate. We're going to gather all that, put that onto the blockchain and then do the average efficacy. And we're going to roll more of that for them. And I'm happy to announce, like we had a bit of a false step at the end of 2018, just because it was, the regulators were about using coins for rewards, uh, crypto based stuff. So we've got a regularly regulator approved model or award system, you know what works just like an Aeroplan it's almost model off the Aeroplan basis. So you, you do stuff, we reward you. And then we pull the retailers through with that and look that beta that we're aggregating is going over two years and 465,000 people is crunching out something like 7 billion data points. It's incredible. Well, and that's, that's just linear. That's not even the smart data. That's not even processed outcomes. That's linear. And so that's what we've done during COVID. And I know it's frustrating because we've been like everybody knew was hungry. I, I get it. I'm new sign, you know, as a shareholder. Um, but what we've done is we've focused on building that company and those data points. Um, and you know, by getting those data points by people wearing things and by buying them and working with seat the sale company, by building our own API to our system. So you're like offer this to your growers, cause they're already selling stuff and they need to sell more. And then we get access to their customers, right? Funding, growing companies using our coin to help fund already established growing companies that are having that gap in funding. Right. They need that extra 2 million by working with crowdfunding, that to be in that cannabis section of it, what do we get access to? Well, we make revenue, but you know, really may we get access to their consumer? And so, yeah, it's all about the consumer and what we're doing different. And there's a lot of, there's some very good smart technology companies. The ones who've been around longer or not, what we're doing is we're focused. This is the tagline of, I think you as being in this space, normally we ask what's your differentiator? What is this? Is it okay? We measure what's happening with a human being at a given point in time, under a set of circumstances when using product a retreat symptom B. And we take capture that point in time when we capture everybody's and then we process it using machine learning and advanced algorithms and games, hundreds, but thousands of other people. So that when we say it, Brad has shoulder bursitis and he's used this and this middle ground X amount of times that over time, the outcome will be this based on him being compared to everybody else. And what comes out of that is you get that end result of a clinical study when you know the formulation, because we don't know the formulation, we're still getting to average efficacy. You see what I mean? We're, we're solving the problem, but in a different way, and only with Hannah's, cause it's not a real medicine. And we do that. And what's really interesting if I grab that information and attach it to all the growing information from a grand Barrington, I now provide a regulator with enough information to make reasonable regulatory frameworks, to allow for the importation and the use. So that's what we've done. And that's what we're working on in here. That's what we've been working on for five months, building those relationships and those inroads with those types of things. And the net end result is like, we have so much demand for the data for the user data. And so if anybody understands, they're like, so how you, how are you going to get it? It's simple. I'm going to give them consumers my own reward based program. And then I'm going to go to retailers and say, Hey, you want to grow your business? Yes, I do. Well, if you use R if you reward this guy, if you take his stuff in and give them to make it a little bit less, but to capture all his cannabis.

Speaker 3: 21:33

Okay. All right. Let's let's um, let's walk through it really slow. Let's walk through it really slow. Sure. I'm patient. Hey, I walk into a cannabis dispensary, retailer and I, whatever my, like you said, my shoulder's hurting. I grab a product from the bar, the bud tender, um, that they suggest in that product is your identifier on that. I take it. It's linked to phone, watch everything, the data points come back to you. What do they go

Speaker 4: 22:19

The way it goes. So first of all, and it's important for everybody to understand this whole system has been built to EDU GDPR slash Tampa standard. Right? Okay. So information that comes from your and experience, there's no tag to use an individual. I care about big numbers, right? I don't need to know your name. I don't need to know this. So once it's temporary, the blockchain, I think what's important to understand is first and foremost, we're going to target the acquisition of 280,000 consumers on our own without the report, we're going to go, Oh, I know. Yeah. So we're going to spend an average cost of$15 a consumer to get them that chunk of money. Um, and we're going to partner and we, and so one of the things, when you look at our recent deck that we're releasing, we're working with the crowd fund, right?

Speaker 3: 23:05

For those listening and watching, I have the doc, you should check it out.

Speaker 4: 23:09

Yes. Thank you for the crowdfunding companies and the seat. That's one reason we're partnering with Canada's crowd funding. And we're also looking at seed sales is because they have consumers. All right. I want to lower my cost of acquisition. It's important that I take those 288 spend money getting them. Right. Cause you gotta remember if I, if somebody wants it, let's say, for example, you download the app and right away, you're in five euros per say for doing it. You're gonna go yeah. Right on. And then you, you enter, you have a list of products and you enter the products you're using and they'll start track it. Now the real question is you got, now you've got, let's say 25 or 30 year olds where you're going to, what do you get to do with them? Now you go to the retailer and the retailer is not using our system. And of course we have our sales outreach to those retailers say, Hey, you know what? Right now, because the way it works in United States planet, and it's a little bit different Europe, people spend 30% of their money at one place. Our objectives help a retailer grow that to 60%. Okay. So they get more so, and here's the thing for working with them, with bringing those products in or those those using, using our product, which is just the basically says an interface on their computer that links with their supply system, by bringing it in and redeeming those rewards and then giving them like 20 bucks worth of, uh, of, uh, you know, purple Coolidge for shoulder bursitis and a certain milligram or, or even an extract or an isolate. What will happen is that guys, all like, man, this is really worth my time. GTAC gave me points that the retailers redeem it. Now here's the cool thing. The retailer hassles point. So what does he do? Like airplanes. He gives them to a consumer, but I don't target. They go over there, right? You fly with air Canada. I don't necessarily use my eye. You're never going to enough points with air Canada actually buy an air Canada ticket, but you can read, just rent a car from budget or state the Marriott, right? You have a C and you'll pass it along. And then he gets more sale from that. And the most important thing. And I think this is what sometimes when we talk about rewards, people miss it. You know, a lot of people use stuff like Fitbit and everything else. If you know why, and they, they, they answer questions that he and they, they gets all saved up this information, you know why? And they know it. That's getting that information because it's good for them. It's helping them. Nobody wants to get a prescription with cannabis and have a bad experience. So why not tap yourself into a system? So the next time you go see your retailer, what comes up LinkedIn is that guy can tell you, that's interesting. Maybe we need to tweak it. The system says to adjust it. So it's not Kentucky windage. That's where the algorithms come in. That's where the AI comes in. And those AI, those AI algorithms and stuff that were developed were by using inputs from some of the top doctors in Israel that were treating at the end and practitioners in Canada to one guy, Adolfo Gonzalez and work with 300,000 Canadians over 25 years, like the true dispensaries and what was the first set. And so what's going to be really interesting is, you know, you'll start off, we've got 50 people all using the same thing and having have efficacy could be high to be low. No we don't. But that's the whole thing. Nobody knows, right? That's our answer that we'll try to apply. But when it's 5,000, it could be a hundred percent different. And that's the exciting thing. It gets smarter as it goes along. That's why I use it. And because it all gets on a blockchain. So people say why the blockchain, Brad. And I go, first of all, it's a private blockchain. So why not just use the database? I go because we need to show a linkage because once the AI gets in the middle of starts making determinations, you have to understand what the correlation to the decision was. And we're talking about tens of millions of data points. Well, it's 6 billion data points. So with your regulator, you can look at it with confidence that the chain of custody is transparency 100%. And so when it comes, and this is what we're focused on, and I've said this before, we have people that work for us that have spent a lot of time working with the UW pushing messages out. I'm going to call it lobbying and pushing messages. And that's one of our, one of our things. So we looked at the demands of regulators and we worked the system backwards and how we built them. And that's what we've got. That's our plan. We're a data com we're a medical cannabis efficacy database. And at the end of it, we're going to have six plus billion, maybe more. I mean, I can never keep up with that way. The mathematicians are doing it for me. Um, and as we go along, we're selling that data. I can't tell you the amount of phone calls I get on a weekly basis saying we want to buy data and you know who, some of it are hedge funds. They want to know the efficacy of growing data. So they can look at that and compare it to their own things and look about where they should be making investments.

Speaker 3: 28:18

Yeah.

Speaker 4: 28:18

Practitioners, universities, other growing companies. Like if we can get, imagine if we had a better dataset before we went into COBIT, how further along we would have been.

Speaker 3: 28:31

Let's let's not even, let's not, let's not go down that rabbit hole. Um, now w let's but let's go to the future. What is your, what is your exit? What, what are you thinking about?

Speaker 4: 28:47

Well, um, it's a two year plan we're modeling and everything, as you saw there two years, it's about acquiring, going out buying 280, a thousand consumers turning those 465 through that kind of reward system, upselling, aggregating all their data and selling that data for a significant amount. Like, you know, like some of the numbers are staggered and you can buy data points of 17 cents for a clinical type question answered, and you can sell for a dollar 20. And I know that because we've had those conversations with providers right. And, or sorry with, for people who want to buy it. And so the bracing for cost or, Oh, yeah, yeah. Yeah. Well, so if anybody's really keen and wants to know, and they want to sign an NDA, I'll be happy to send over the cash flow modeling. Right. If you're a serious investor. Right. Um, but, uh, yeah, so it actually breaks it down. It's a huge look. It's a, it's a 70 to a 75% margin business. And here's the thing. When we talk about 17 cents on a dollar 20 out, that's a onetime sale. It doesn't mean there can't be multiple, but you never know how big it's going to be. You don't know if you're going to sell it 10 times, 30 times, 40 times until it has net no Valley. The exit is the net exit out of this is a very cash rich business. And I think when you saw that and like, when you look at, like you saw on the numbers and the margin, there's a lot of money in the till. And most importantly, that data with those patents, that's the exit. Like, somebody's like, you know, if I was a pharmaceutical company, I would want somebody like GCC to go do all the heavy lifting and go figure this issue. And then swoop in with those incredibly endless deep pockets. Um, our job is to build a TAC and I consider that foreign 65,000 users, you know, and a lot of people don't know this. And so I'm happy to talk about it is that that I've taken the algorithm, the next level with the, with the, with the, uh, the biometrics, by being able to take in our app and interconnecting with an Apple watch app or Apple watch or whatever the case is, whatever device we can connect to. It's huge. It lowers cause everybody, nobody wants a new watch. They want to work with an existing hardware. They got and bringing those biometrics in because your heart rate doesn't lie. So if you're hitting something too hard and you're like, eh, you're vibrating what we're going to measure that. And then we're going to correlate that. And then we're going to do that. And then, you know, what we're going to do is we're going to provide that to make you growers make better products, regulators write better regulations and doctors make informed decisions and that in itself, plus the Patton, that's the asset, what that looks like notes, but I'm going to have 6 billion, 6 billion plus process data points to make money off of up until then. And to hopefully somebody will come along and say, you know, this is a methodology that will actually work.

Speaker 3: 31:59

And that is the note. We are going to end this program on Brad. Thank you so much for taking the time. Um, thank you for your listing. We value you and your company, um, greatly please continue to stay safe. And if you're watching, don't forget to, or, or, and, or listening, don't forget to subscribe to CSC underscore TV. You can check us out on Instagram, YouTube, Facebook, uh, LinkedIn, uh, this interview will be broadcast on any of those various channels. This has been very familiar. Your host from the Canadian securities exchange with global cannabis application Corp. Thank you goodbye.

Speaker 1: 32:40

Hey, it's James here reminding you that if you just enjoyed this episode of hashtag finance, there's a lot more, make sure you subscribe to this show available on Apple podcasts, Spotify, SoundCloud, Stitcher, and Google podcast shows coming out at least twice a week. So please do not miss out. Also, if you're on Instagram, please don't forget to follow us at Canadian exchange. That's all one word Canadian exchange. We're hosting live daily content with great guests, discussing the capital markets, entrepreneurship, investing, and much more. And finally, if you like video, please subscribe to CSC space TV, that CSC space TV on YouTube. You can find more great stuff, including exclusive series content like cannabis month, 2020, and our new series investing in psychedelics as always. Thank you for listening.